Get the Stockscreener App
40.61
3.81%
-1.61
Pre-market:
41.08
0.47
+1.16%
Crispr Therapeutics Ag Stock (CRSP) Latest News
CRISPR Therapeutics AG (CRSP): Among Cathie Wood’s Top Stock Picks for 2025 - Insider Monkey
HC Wainwright Begins Coverage on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
March 28th Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.3%Should You Sell? - MarketBeat
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - MSN
KBC Group NV Has $2.38 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
FY2024 Earnings Estimate for CRSP Issued By HC Wainwright - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2%Here's Why - MarketBeat
Crispr Therapeutics: Why I’ve Become Even More Bullish (Rating Upgrade) (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics (NASDAQ:CRSP) Trading 3.7% HigherStill a Buy? - MarketBeat
Gene Editing Therapy Casgevy Now Funded In 8 Countries But French Access Withdrawn - Pink Sheet
Analysts Offer Predictions for CRSP FY2024 Earnings - MarketBeat
(CRSP) Trading Report - Stock Traders Daily
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1.2%What's Next? - MarketBeat
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy Recommendation - MSN
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates? - Yahoo Finance
HC Wainwright Initiates CRISPR Therapeutics at Buy With $65 Price Target -February 03, 2025 at 07:40 am EST - Marketscreener.com
HC Wainwright Initiates Coverage on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG: A Compelling Buy Amidst Gene Editing Innovation and Market Growth Potential - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 0.7%Here's Why - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Update - MarketBeat
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? - The Motley Fool
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 0.8%Here's What Happened - MarketBeat
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 0.5%Still a Buy? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2.7%What's Next? - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Trimmed by Patriot Financial Group Insurance Agency LLC - MarketBeat
Slow Capital Inc. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox - Benzinga
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.1%Time to Sell? - MarketBeat
Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why - Yahoo Finance
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - MSN
CRISPR Therapeutics Readies Major Gene Therapy Updates for Guggenheim Conference - StockTitan
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.7%Here's What Happened - MarketBeat
Following a 34% decline over last year, recent gains may please CRISPR Therapeutics AG (NASDAQ:CRSP) institutional owners - Simply Wall St
Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $78.38 - MarketBeat
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last? - MSN
(CRSP) Proactive Strategies - Stock Traders Daily
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
FY2024 EPS Estimates for CRSP Increased by Leerink Partnrs - MarketBeat
CRSP March 7th Options Begin Trading - Nasdaq
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - Benzinga
Cantor Fitzgerald Estimates CRSP FY2025 Earnings - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):